

Form PTO-1449 (Modified) INFORMATON DISCLOSURE STATEMENT BY APPLICANT <i>(Use Several Sheets if Necessary)</i>	ATTORNEY DOCKET NO.	HOPEP002
	APPLICATION NO.	09/722,096
	APPLICANT	Ernest G. HOPE
	FILING DATE	11/22/2000
	ART UNIT	1643
PAGE 1 OF 2		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	CITE NO.	COUNTRY OR PATENT OFFICE	DOCUMENT NO.	PUBLICATION DATE	CLASS	SUB- CLASS	TRANSLATION YES NO
	1	WO	99/46365 A	9/16/1999			
	2	WO	00/10603 A	3/2/2000			

NONPATENT DOCUMENTS

EXAMINER INITIAL	CITE NO.	AUTHOR, TITLE, PLACE (E.G. JOURNAL) OF PUBLICATION, DATE
	3	CARSWELL et al. (2000), "Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor," <i>Biotechnol. Bioeng.</i> 68(3):328-338 (abstract only).
	4	HILLMAN et al. (1994), "Expansion of activated lymphocytes obtained from renal cell carcinoma in an automated hollow fiber bioreactor," <i>Cell Transplant.</i> 3(4):263-71 (abstract only).
	5	HOPE (1999), "Heat Shock Protein 47 Mediated Response Modulation on Non-MHC I Restricted Cytotoxic T Lymphocytes," Dissertation Abstracts International 61(1B):178.
	6	HOPE (1999), "Heat Shock Protein 47 Mediated Response Modulation on Non-MHC I Restricted Cytotoxic T Lymphocytes," Stanford University (complete Ph.D. dissertation).
	7	HOPE et al. (1998), "Recombinant huHsp47 Is a Novel Selective Immune-Suppressant Agent for Adoptive Immunotherapy (AI): It Protects Endothelial Cells from Damage by AI Cells But Does Not Cause Reduction of Tumor Surveillance Activity," <i>Lymphocytes II</i> Abstract #1399, page 341A (from Blood 92(10 Suppl. 1 Part 1/2)).
	8	HOPPE et al., "Hsp47, a housekeeping serine protease inhibitor and collagen chaperone shares homology with the α_1 -domain of HLA-a2 and inhibits non-MHC I restricted T and NK cytotoxicity against vascular endothelial cells via a novel mechanism," <i>Lymphocytes - Differentiation and Effectors</i> Abstract #2019.
	9	HU et al. (1999), "Targeting Tumor Vasculature Endothelial Cells and Tumor Cells for Immunotherapy of Human Melanoma In a Mouse Xenograft Model," <i>Proc. Natl. Acad. Sci. USA</i> 96:8161-8166.
	10	KANEKO et al. (1994), "Cytotoxicity of Cytokine-Induced Killer Cells Coated with Bispecific Antibody Against Acute Myeloid Leukemia Cells," <i>Leukemia and Lymphoma</i> 14:219-229.
	11	LEFTEROVA et al. (1998), "Targeting of CD3+CD56+ Human Immunologic Effector Cells Against CD19+ Leukemia and Lymphoma Cells by the Use of Anti CD3 Monoclonal Antibody," <i>Lymphoma Therapy - Pre-Clinical Investigation</i> Abstract #1003, page 264a (from Blood 92(10 Suppl. 1 Part 1/2)).
	12	SCHMIDT-WOLF et al. (1997), "Activated T cells and cytokine-induced CD3+CD56+ killer cells," <i>Annals of Hematology</i> 74(2):51-56.

EXAMINER	DATE CONSIDERED
----------	-----------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use Several Sheets if Necessary)</i>	ATTORNEY DOCKET NO.	HOPEP002
	APPLICATION NO.	09/722,096
	APPLICANT	Ernest G. HOPE
	FILING DATE	11/22/2000
	ART UNIT	1643
PAGE 2 OF 2		

NONPATENT DOCUMENTS

EXAMINER INITIAL	CITE NO.	AUTHOR, TITLE, PLACE (E.G. JOURNAL) OF PUBLICATION, DATE
	13	SCHMIDT-WOLF et al. (1999), "Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma," <i>British Journal of Cancer</i> 81(6):1009-1016 (abstract only).
	14	AU Office Action (3/5/2004) from AU Patent Application No. 24258/01 (11/22/2000), now abandoned.
	15	AU Office Action (9/14/2005) from AU Patent Application No. 24258/01 (11/22/2000), now abandoned.
	16	AU Office Action (11/18/2005) from AU Patent Application No. 24258/01 (11/22/2000), now abandoned.
	17	EP Supplementary Search Report (8/16/2004) from Patent Publication No. EP1231840 (8/21/2002) (HOPEP002EP).
	18	EP Office Action (10/17/2005) from Patent Publication No. EP1231840 (8/21/2002) (HOPEP002EP).
	19	EP Office Action (3/29/2007) from Patent Publication No. EP1231840 (8/21/2002) (HOPEP002EP).
	20	EP Office Action (6/28/2007) from Patent Publication No. EP1231840 (8/21/2002) (HOPEP002EP).
	21	International Search Report (2/26/2001) from Patent Publication No. WO01/37671 (5/31/2001) (HOPEP002WO).
	22	International Preliminary Examination Report (9/26/2002) from Patent Publication No. WO01/37671 (5/31/2001) (HOPEP002WO).

EXAMINER	DATE CONSIDERED
----------	-----------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.